Stable, high-titer expression starts with the right integration tool
Engineered from butterflies
Asimov’s Chrysalis is a wholly-owned, proprietary transposase engineered from the genomes of multiple butterfly species, then systematically optimized to enhance its performance in a biomanufacturing context. The result is an integration tool that delivers higher titers, greater expression stability, and faster cell recovery than conventional transposases.
Because Asimov owns the Chrysalis transposase sequence outright, it powers every Asimov cell line development campaign. Chrysalis is also available for licensing to teams that want to bring it in-house. It can be licensed for any application from manufacturing biologics to therapeutic use in genetic medicines.
What is a transposase?
Transposases are enzymes found in nature with a precise molecular function: they cut DNA out of one location and paste it into another. In cell line development, this mechanism is applied to take a therapeutic transgene from a transfected plasmid and integrate it directly into the host cell's genome.
Chrysalis for Cell Line Development
Novel use case:
Transposase-mediated rapid manufacturing
Chrysalis generates high-titer stable material in as little as 14 days post transfection, offering an alternative to transient transfection. This gives discovery and CMC teams consistent material from the same bioproduction system used at scale.
From stable transfection to material in 15 days…
…as a valuable alternative to transient manufacturing
Better, translatable decisions
Material generated in the same stable-cell context used downstream.
Fast, high titers
Achieve up to 2.3 g/L in just 15 days.
Cost-efficient
Compared to transient, less DNA used for testing, and pools (no-DNA) can be used for repeat, scalable manufacturing.
License Chrysalis for your workflow
Bring Chrysalis in-house by licensing the transposase directly for use in your own facility for biologics production and genetic medicines.
License it as a standalone tool or as part of the full CHO Edge System.
We provide tools for you to develop a cell line
We will ship the software, cells, and genes you need to design your cell line in-house.
You design DNA
You use our software to design and optimize genetic constructs using best-in-class parts and models.
We build DNA
We will ship the software, cells, and genes you need to design your cell line in-house.
You transfect cells
You transfect and generate stable cell lines and use our software for data analysis.
You request producer cells
You request a producer cell line for a biologic or gene therapy.
We do cell line development
We do cell line development and process development at our site.
We share progress
We share progress and data with you using our software.
We ship you producer cell banks
We ship you clonal cell banks and transfer the process to your site.
Bring Chrysalis in-house by licensing the transposase directly for use in your own facility for biologics production and genetic medicines.
License it as a standalone tool or as part of the full CHO Edge System.
Chrysalis also powers Asimov's industry-leading CHO Edge cell line development service. Learn more.
